Pregabalin Capsule
Product Images NDC 80425-0027

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0027). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation

A medical formula calculating creatinine clearance (CLCr) involving variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor adjusted for female patients. The formula includes multiplication and division among these variables.*

FDA Label Image

Fig 1

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for different doses of Pregabalin (200 mg, 100 mg, and 25 mg three times a day) compared to placebo. The graph shows improvement trends for these treatment groups over increasing percentage thresholds of pain relief.*

FDA Label Image

Fig 10

A survival curve graph comparing estimated percentage of subjects without LTR over 180 days between Pregabalin and Placebo groups. The x-axis represents days from 0 to 180, and the y-axis represents the estimated percentage of subjects without LTR from 0% to 100%. Two lines depict the data: a solid line for Pregabalin and a dashed line for Placebo, showing higher survival rates for Pregabalin throughout the duration.*

FDA Label Image

Fig 11

A line graph comparing the percentage of subjects improved over various percent improvements from baseline to week 12 BOCF between Pregabalin and Placebo. The x-axis represents percent improvement from baseline, and the y-axis shows percent of subjects improved. Pregabalin shows a higher percentage of subjects improved than placebo across the range.*

FDA Label Image

Fig 12

A line graph comparing the percentage of subjects improved from baseline to week 16 for Pregabalin (solid line) versus Placebo (dashed line). The x-axis represents percent improvement from 0 to 100, and the y-axis represents the percent of subjects improved. The chart shows that Pregabalin consistently has a higher percentage of subjects improved compared to Placebo across the improvement range.*

FDA Label Image

Fig 2

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares two groups: patients receiving Pregabalin 100 mg three times a day and those receiving placebo, showing a higher percentage of patients improved in the Pregabalin group across various levels of pain improvement.*

FDA Label Image

Fig 3

A line chart illustrating the percent of patients improved as a function of percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, showing different efficacy trends across varying pain improvement percentages.*

FDA Label Image

Fig 4

A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline, with lines representing each treatment group's response levels.*

FDA Label Image

Fig 5

A line chart showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with the y-axis representing percent of patients improved and the x-axis percent improvement in pain from baseline.*

FDA Label Image

Fig 6

A bar graph comparing responder rates (%) in two clinical studies (E1 and E3) for Pregabalin doses versus placebo. Study E1 shows response rates for placebo and Pregabalin capsules at 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day doses. Study E3 compares placebo with Pregabalin 600 mg/day given either once daily (QD) or three times daily (TID). The graph indicates increasing responder rates with higher Pregabalin doses compared to placebo.*

FDA Label Image

Fig 7

A line graph depicting seizure reduction as median percentage change from baseline plotted against dose in mg/day. The graph compares four studies, labeled E1, E2, and E3 with BID or TID dosing, showing statistical significance levels (p-values) at various dose points up to 600 mg/day. Placebo dose is indicated at zero on the dose axis, with significant p-values noted for treatment groups.*

FDA Label Image

Fig 9

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Four lines compare Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo, showing trends in patient response across varying levels of pain improvement.*

FDA Label Image

Pregabalin 50 mg Cap Qty 60 80425 0027

Label for Pregabalin 50 mg oral capsules, package of 60, manufactured by Advanced Rx of Tennessee, LLC. The label includes the NDC 80425-0027-01, lot number 60PRE501221, and an expiration date of 11/2022. Storage instructions specify room temperature between 20° and 25°C (68° to 77°F).*

FDA Label Image

Structure

Chemical structure diagram of pregabalin showing its molecular arrangement with key functional groups labeled including CO2H and NH2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.